JPWO2020049166A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020049166A5 JPWO2020049166A5 JP2021512682A JP2021512682A JPWO2020049166A5 JP WO2020049166 A5 JPWO2020049166 A5 JP WO2020049166A5 JP 2021512682 A JP2021512682 A JP 2021512682A JP 2021512682 A JP2021512682 A JP 2021512682A JP WO2020049166 A5 JPWO2020049166 A5 JP WO2020049166A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- dithiol
- formula
- thione
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- -1 nitro, carboxy Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000008351 acetate buffer Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- FZNSULGQTRGDDF-UHFFFAOYSA-N 4-(4-hydroxyphenyl)dithiole-3-thione Chemical compound C1=CC(O)=CC=C1C1=CSSC1=S FZNSULGQTRGDDF-UHFFFAOYSA-N 0.000 claims 1
- GEOXNKHTZAUVBM-UHFFFAOYSA-N 4-(5-hydroxyiminodithiol-3-yl)phenol Chemical compound OC1=CC=C(C=C1)C1=CC(SS1)=NO GEOXNKHTZAUVBM-UHFFFAOYSA-N 0.000 claims 1
- KDJVJTMHWXZZJJ-UHFFFAOYSA-N 5-(1-benzofuran-5-yl)dithiole-3-thione Chemical compound O1C=CC2=C1C=CC(=C2)C1=CC(SS1)=S KDJVJTMHWXZZJJ-UHFFFAOYSA-N 0.000 claims 1
- HLFFXEFJKQLPTQ-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-1,2,4-dithiazole-3-thione Chemical compound OC1=CC=C(C=C1)C1=NC(SS1)=S HLFFXEFJKQLPTQ-UHFFFAOYSA-N 0.000 claims 1
- XXDYQIINMXOSSO-UHFFFAOYSA-N 5-(4-hydroxyphenyl)dithiol-3-one Chemical compound C1=CC(O)=CC=C1C1=CC(=O)SS1 XXDYQIINMXOSSO-UHFFFAOYSA-N 0.000 claims 1
- MYTUEHUXUXSJCN-UHFFFAOYSA-N 5-(5-sulfanylidenedithiol-3-yl)-3H-1,3-benzoxazol-2-one Chemical compound OC=1OC2=C(N=1)C=C(C=C2)C1=CC(SS1)=S MYTUEHUXUXSJCN-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- CMAFOEYOQDEIOR-UHFFFAOYSA-N 6-(5-sulfanylidenedithiol-3-yl)-3H-1,3-benzothiazol-2-one Chemical compound OC1=NC2=CC=C(C=C2S1)C1=CC(=S)SS1 CMAFOEYOQDEIOR-UHFFFAOYSA-N 0.000 claims 1
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000007932 Progeria Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- IWBBKLMHAILHAR-UHFFFAOYSA-N chembl402341 Chemical compound C1=CC(O)=CC=C1C1=CC(=S)SS1 IWBBKLMHAILHAR-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862727691P | 2018-09-06 | 2018-09-06 | |
| EP18306172 | 2018-09-06 | ||
| EP18306172.0 | 2018-09-06 | ||
| US62/727,691 | 2018-09-06 | ||
| PCT/EP2019/073873 WO2020049166A1 (en) | 2018-09-06 | 2019-09-06 | Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021536472A JP2021536472A (ja) | 2021-12-27 |
| JP2021536472A5 JP2021536472A5 (https=) | 2022-09-15 |
| JPWO2020049166A5 true JPWO2020049166A5 (https=) | 2022-09-15 |
| JP7362725B2 JP7362725B2 (ja) | 2023-10-17 |
Family
ID=67841092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512682A Active JP7362725B2 (ja) | 2018-09-06 | 2019-09-06 | アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12295969B2 (https=) |
| EP (1) | EP3846856A1 (https=) |
| JP (1) | JP7362725B2 (https=) |
| KR (1) | KR20210054540A (https=) |
| CN (1) | CN113038969A (https=) |
| AU (2) | AU2019336943A1 (https=) |
| BR (1) | BR112021003997A2 (https=) |
| CA (1) | CA3111886A1 (https=) |
| IL (1) | IL281161B2 (https=) |
| MX (1) | MX2021002611A (https=) |
| WO (1) | WO2020049166A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022123038A1 (en) * | 2020-12-10 | 2022-06-16 | OP2 Drugs | Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries |
| EP4112051A1 (en) * | 2021-06-30 | 2023-01-04 | Op2 Drugs | Anethole trithione for the treatment of vasculitides |
| CN114558004B (zh) * | 2022-03-29 | 2023-08-11 | 奎马特里克斯有限公司 | Qtx125药物制剂 |
| CN115738757B (zh) * | 2022-11-24 | 2024-03-29 | 中国海洋大学 | 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262165A (en) | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| CA2222133C (en) | 1995-06-07 | 2002-12-24 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| AU5474198A (en) * | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| CN1771938A (zh) | 2004-11-09 | 2006-05-17 | 胡才忠 | 茴三硫脂质体及其制备方法 |
| JP6876047B2 (ja) * | 2015-09-08 | 2021-05-26 | オーピーツー ドラッグス | ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物 |
| BR112018004518A2 (pt) * | 2015-09-08 | 2019-03-19 | OP2 Drugs | compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais |
| AU2018232799B2 (en) * | 2017-03-07 | 2021-11-25 | Centre Hospitalier Universitaire De Bordeaux | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production |
-
2019
- 2019-09-06 AU AU2019336943A patent/AU2019336943A1/en not_active Abandoned
- 2019-09-06 WO PCT/EP2019/073873 patent/WO2020049166A1/en not_active Ceased
- 2019-09-06 JP JP2021512682A patent/JP7362725B2/ja active Active
- 2019-09-06 EP EP19762427.3A patent/EP3846856A1/en active Pending
- 2019-09-06 IL IL281161A patent/IL281161B2/en unknown
- 2019-09-06 MX MX2021002611A patent/MX2021002611A/es unknown
- 2019-09-06 BR BR112021003997-0A patent/BR112021003997A2/pt unknown
- 2019-09-06 US US17/273,928 patent/US12295969B2/en active Active
- 2019-09-06 KR KR1020217009152A patent/KR20210054540A/ko not_active Ceased
- 2019-09-06 CA CA3111886A patent/CA3111886A1/en active Pending
- 2019-09-06 CN CN201980072663.5A patent/CN113038969A/zh active Pending
-
2025
- 2025-06-03 AU AU2025204144A patent/AU2025204144A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007284537B2 (en) | Triazole compounds that modulate HSP90 activity | |
| RU2733750C2 (ru) | Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение | |
| AU2006214164B2 (en) | Isoxazole combretastin derivatives for the treatment of disorders | |
| JP2021536472A5 (https=) | ||
| US20100279410A1 (en) | Compounds for the treatment of proliferative disorders | |
| JP2011524422A5 (https=) | ||
| JP2007504284A5 (https=) | ||
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| JP2005535731A5 (https=) | ||
| US20100093670A1 (en) | Compounds for the treatment of angiogenesis | |
| FR2512449A1 (fr) | Quinoleinium-betaines de cephalosporine et leur application pharmacolique | |
| JP2010511687A5 (https=) | ||
| FR2512448A1 (fr) | Isoquinoleinium-betaines de cephalosporine et son application pharmaceutique | |
| WO2023038088A1 (ja) | トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法 | |
| US7662842B2 (en) | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents | |
| EP3618827B1 (en) | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof | |
| JPWO2020049166A5 (https=) | ||
| KR101536488B1 (ko) | 이미다졸 유도체, 그의 제조 방법 및 용도 | |
| FR2610628A2 (fr) | Nouveaux derives de l'acide 1-dethia 2-thia cephalosporanique, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant | |
| CN102190656B (zh) | 含有五元杂环的噁唑烷酮抗菌素 | |
| RU2021108635A (ru) | Композиция, содержащая сульфобутиловый эфир бета-циклодекстрина и соединение формулы (I) | |
| JP2004224802A (ja) | 抗菌剤 | |
| JPWO2020028461A5 (https=) | ||
| CN111991398B (zh) | 苯并哒嗪类化合物在制备sost蛋白抑制剂中的应用 | |
| US5599825A (en) | Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same |